[Federal Register: March 23, 1998 (Volume 63, Number 55)]
[Notices]               
[Page 13875]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr23mr98-101]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

 
Manufacturer of Controlled Substances Notice of Registration

    By Notice dated October 22, 1997, and published in the Federal 
Register on November 4, 1997, (62 FR 59735), Guilford Pharmaceuticals, 
Inc., 6611 Tributary Street, Baltimore, Maryland 21224, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of cocaine (9041), a basic class 
of controlled substance listed in Schedule II.
    The firm plans to manufacture cocaine as a final intermediate for 
the production of dopascan injection. Cocaine derivative are Schedule 
II controlled substances in the cocaine basic class.
    DEA has considered the factors in Title 21, United States Code, 
Section 823(a), as well as information provided by other bulk 
manufacturers, and determined that the registration of Guilford 
Pharmaceuticals, Inc. to manufacturer cocaine is consistent with the 
public interest at this time. Therefore, pursuant to 21 U.S.C. 823 and 
28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of 
Diversion Control, hereby orders that the application submitted by the 
above firm for registration as a bulk manufacturer of the basic class 
of controlled substance listed above is granted.

    Dated: March 10, 1998.
John H. King,
Deputy Assistant Administrator, Office of Division Control, Drug 
Enforcement Administration.
[FR Doc. 98-7383 Filed 3-20-98; 8:45 am]
BILLING CODE 4410-09-M